Tatsunori Shimoi, Head of Physician at National Cancer Center Hospital, Japan, shared a post on X:
“We report JBCRG-C08/ATTRIBUTE in npjBreastCancer, a prospective real-world study of atezolizumab + nab-paclitaxel for PD-L1+ metastatic TNBC in Japan.
151 pts from 79 sites were enrolled. irAEs: 30.9%, SAEs: 16.8%, median PFS: 5.6 mo, median OS: 22.5 mo. No new safety signals were observed, but patients with autoimmune disease require careful monitoring.”
Title: Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE
Authors: Tatsunori Shimoi, Nobuhiro Shibata, Masahiro Kitada, Michiko Tsuneizumi, Mitsugu Yamamoto, Yukinori Ozaki, Yumi Fujimoto, Sayuri Akiyoshi, Naoki Hashimoto, Miki Yamaguchi, Yutaka Yamamoto, Norikazu Masuda, Hiroshi Tada, Takashi Yamanaka, Yuichiro Kikawa, Tetsuhiko Taira, Shizuka Nakagawa, Taizo Takahashi, Mari S. Oba, Naoki Niikura
Read the Full Article.
